Abstract
Background
Many cancers display alterations in methylation patterns of CpG islands--stretches of DNA rich in CpG dinucleotides often associated with gene promoters that are involved in initiation of gene transcription. This methylation may perturb expression of genes critical to the regulation of cell proliferation. Aberrant methylation is not limited to a few genes or to promoter regions but has been found on a genome-wide scale in a variety of neoplasias, including colorectal cancer and acute myelogenous leukemia. Our goal was to characterize, in a quantitative manner, the profiles of abnormally methylated genes that may be specific for different cancers.Methods
Using a quantitative assay, methylation-sensitive single nucleotide primer extension (MS-SNuPE), we have analyzed the methylation levels of promoter and exonic (coding region) CpG islands of two cyclin-dependent kinase inhibitors [p15(INK4B) and p16(INK4A)] and the PAX6 gene, which encodes a transcriptional factor involved in neuronal proliferation, in DNA samples taken from patients with chronic myelogenous leukemia, acute myelogenous leukemia, myelodysplastic syndrome, and colorectal cancer.Results
De novo methylation of all three exonic loci in tumors--relative to baseline levels found in nontumor tissue or blood--was observed in hematologic neoplasias and in solid tumors as well as in normal colonic tissue. However, methylation of promoter regions was more limited. Moreover, two different patterns of promoter methylation distinguished the leukemias from colorectal cancer: p15 promoter hypermethylation was found only in the leukemias, and p16 promoter hypermethylation occurred only in colon tumors. However, we did not address this issue prospectively; therefore, such an observation is only hypothesis generating.Conclusions
The methylation patterns that we observed suggest that exonic CpG islands are more susceptible to de novo methylation than promoter islands and that methylation may be seeded in exonic regions, from which it can spread to other islands, including promoter regions. Subsequent selection of cells with a growth advantage conferred by spread of methylation into and inactivation of a particular promoter might then contribute to the genesis of a specific type of cancer.Full text links
Read article at publisher's site: https://doi.org/10.1093/jnci/93.19.1465
Read article for free, from open access legal sources, via Unpaywall: https://academic.oup.com/jnci/article-pdf/93/19/1465/10887864/1465.pdf
References
Articles referenced by this article (27)
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies.
Cancer Res, (5):837-841 1997
MED: 9041182
Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Cancer Res, (20):4531-4535 1995
MED: 7553622
Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
Leukemia, (6):845-859 1998
MED: 9639410
DNA hypermethylation in tumorigenesis: epigenetics joins genetics.
Trends Genet, (4):168-174 2000
MED: 10729832
The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines.
Cancer Res, (6):1245-1252 1998
MED: 9515812
PAX6 methylation and ectopic expression in human tumor cells.
Int J Cancer, (2):179-185 2000
MED: 10861471
Polymorphic DNA region adjacent to the 5' end of the human insulin gene.
Proc Natl Acad Sci U S A, (9):5759-5763 1981
MED: 6272317
Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE).
Nucleic Acids Res, (12):2529-2531 1997
MED: 9171109
Title not supplied
J Am Stat Assoc 1963
Show 10 more references (10 of 27)
Citations & impact
Impact metrics
Article citations
Unraveling the Progression of Colon Cancer Pathogenesis Through Epigenetic Alterations and Genetic Pathways.
Cureus, 16(5):e59503, 02 May 2024
Cited by: 0 articles | PMID: 38826873 | PMCID: PMC11143495
Review Free full text in Europe PMC
Epigenetic Drugs and Their Immune Modulating Potential in Cancers.
Biomedicines, 10(2):211, 19 Jan 2022
Cited by: 5 articles | PMID: 35203421 | PMCID: PMC8868629
Review Free full text in Europe PMC
Epigenetic and Transcriptional Control of the Opioid Prodynorphine Gene: In-Depth Analysis in the Human Brain.
Molecules, 26(11):3458, 07 Jun 2021
Cited by: 2 articles | PMID: 34200173 | PMCID: PMC8201134
Review Free full text in Europe PMC
DNA hypermethylation in disease: mechanisms and clinical relevance.
Epigenetics, 14(12):1141-1163, 08 Jul 2019
Cited by: 150 articles | PMID: 31284823 | PMCID: PMC6791695
Review Free full text in Europe PMC
DNA methylation in thyroid cancer.
Endocr Relat Cancer, 26(7):R415-R439, 01 Jul 2019
Cited by: 49 articles | PMID: 31035251
Review
Go to all (88) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes.
Leukemia, 14(4):586-593, 01 Apr 2000
Cited by: 31 articles | PMID: 10764143
Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia.
Cancer Res, 59(15):3730-3740, 01 Aug 1999
Cited by: 182 articles | PMID: 10446989
Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia.
Leuk Res, 24(1):39-46, 01 Jan 2000
Cited by: 67 articles | PMID: 10634644
Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
Leukemia, 12(6):845-859, 01 Jun 1998
Cited by: 256 articles | PMID: 9639410
Review
Funding
Funders who supported this work.
NCI NIH HHS (2)
Grant ID: R35CA49758
Grant ID: P01CA55164